Creo Medical Group plc

("Creo", the "Company" or the "Group")

Directorate changes

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that John Bradshaw, Senior Independent Non-Executive Director, has stood down from the Board with immediate effect, in-line with the previous announcements of his planned retirement from the role having served as a Non-Executive Director since IPO in 2016.

As reported in the 2024 AGM statement, John had informed the Board of his intention to retire ahead of the 2025 AGM. John has remained in his role to ensure stability during the last 12 months whilst the Company transitioned to its new leadership model.

Ivonne Cantu, Non-executive Director of Creo, has agreed to act as interim Audit Committee chair whilst the Company identifies an appropriate appointment to the Board as replacement for the Audit Committee chair role. John will be available to support Ivonne during this interim role and to the future incoming Audit Committee chair to ensure an orderly handover.

Furthermore, Brent Boucher will move into the role of Remuneration Committee chair in place of Ivonne Cantu. Ivonne will continue to remain a member of the Remuneration Committee.

Kevin T. Crofton, Non-Executive Chairman, commented:

"I would like to thank John for his service to the Company. John has helped guide and lead Creo with professionalism and pragmatism during his nine-year tenure from IPO, and has provided much welcome support to me and the team as we've continued to build the Company's governance framework."

For further information please contact: 

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com